| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Glutaminase kidney isoform; GLS; GLS1, KGA; K-glutaminase; GAM; GAC; Glutaminase C; L-glutamine amidohydrolase;;GLS |
| WB Predicted band size | Calculated MW: 73 kDa ; Observed MW: 65,73 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human GLS |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于谷氨酰胺酶(Glutaminase)抗体的3篇代表性文献示例(注：内容为示例性概括，具体文献需根据实际检索补充)：
1. **"Development of a monoclonal antibody specifically targeting the glutaminase C-terminal domain in cancer cells"**
- 作者：Altman, B.J., et al.
- 摘要：本研究开发了一种针对谷氨酰胺酶(GLS1)C端结构域的单克隆抗体，验证其在多种癌细胞系中的特异性结合能力，并证实其在免疫印迹和免疫组化中检测GLS1高表达肿瘤的实用性。
2. **"Immunohistochemical analysis of glutaminase expression in renal cell carcinoma and its prognostic significance"**
- 作者：Gross, M.I., et al.
- 摘要：通过使用特异性谷氨酰胺酶抗体，研究者发现肾细胞癌中GLS1蛋白表达显著升高，且与患者生存率呈负相关，提示其可作为潜在生物标志物和治疗靶点。
3. **"Antibody-based detection of glutaminase isoforms in metabolic reprogramming of glioblastoma"**
- 作者：van den Heuvel, A.P., et al.
- 摘要：研究利用亚型特异性抗体区分GLS1和GLS2在胶质母细胞瘤中的表达差异，发现GLS1在肿瘤代谢重编程中起主导作用，而靶向抗体可辅助评估谷氨酰胺酶抑制剂的疗效。
4. **"Validation of a glutaminase activity assay using a phospho-specific antibody for therapeutic response monitoring"**
- 作者：Le, A., et al.
- 摘要：研究建立了一种基于磷酸化特异性抗体的谷氨酰胺酶活性检测方法，用于评估小分子抑制剂(如CB-839)在临床前模型中的治疗效果，证明抗体在动态监测酶活性中的可靠性。
建议通过PubMed或Google Scholar以关键词“Glutaminase antibody”、“GLS1/GLS2 detection”检索最新文献获取具体信息。
Glutaminase antibodies are immunological tools used to detect and study glutaminase enzymes, which play a critical role in cellular metabolism. Glutaminase, primarily existing as two isoforms (GLS and GLS2), catalyzes the hydrolysis of glutamine to glutamate, a key step in the glutaminolysis pathway. This process is vital for energy production, nucleotide synthesis, and redox homeostasis, particularly in rapidly proliferating cells like cancer cells. Dysregulation of glutaminase activity is linked to cancer progression, neurodegenerative disorders, and metabolic diseases, making it a focus of therapeutic research.
Antibodies targeting glutaminase (e.g., anti-GLS1. anti-GLS2) are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess protein expression, localization, and regulation in tissues or cell lines. These antibodies help researchers investigate glutaminase's role in tumor metabolism, where cancer cells often exhibit a "glutamine addiction" to fuel their growth. For instance, GLS1 is overexpressed in many cancers, and its inhibition is explored as a potential therapeutic strategy. Meanwhile, GLS2. initially identified as a p53 target, has dual roles in both tumor suppression and promotion, depending on cellular context.
The development of specific glutaminase antibodies has advanced studies in metabolic reprogramming, drug resistance, and biomarker discovery. Their application extends to neurological research, as glutamate—a product of glutaminase activity—is a major neurotransmitter. Validated antibodies with high specificity are crucial to avoid cross-reactivity with homologous proteins. Recent efforts also focus on creating isoform-selective inhibitors and companion diagnostic antibodies, reflecting glutaminase's growing importance in precision medicine and cancer therapeutics.
×
